PeptideLabs Logo
PeptideLabs
All profiles

KLOW blend

Non-standardised blend · Blends & catalogue terms

Not a standardised medicinal name. Linked to skin, inflammation and repair themes; composition and effects are unconfirmed.

Not FDA/EMA approved
LibraryNo account · this device only

Also known as: Klow Glow · BPC-157 + GHK-Cu + TB-500 + KPV

Use at a glance

KLOW blend

Not a standardised medicinal name. Linked to skin, inflammation and repair themes; composition and effects are unconfirmed.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
1.25 mg GHK-CuKPV: 250 µgBPC-157: 250 µgTB-500: 250 µgScale in the source: 7.5 U
How often?
once per day
What time of day?
not reliably established
What period?
Week 1–2

A U figure only applies to the source's exact composition, concentration and device scale. Without all three, it cannot be transferred to another blend vial or pen.

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

How is it used?
Identify every ingredient and its amount first. The same blend name can refer to different products.
Does it need mixing?
Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.
View preparationCheck sources
Overview of all entries

  • KLOW blend · Week 1–2

    Online report · not medically verified

    1.25 mg GHK-Cu + 250 µg × KPV/BPC-157/TB-500 · 7.5 U · once per day · not reliably established

  • KLOW blend · Week 3–4

    Online report · not medically verified

    2.5 mg GHK-Cu + 500 µg × KPV/BPC-157/TB-500 · 15 U · once per day · not reliably established

  • KLOW blend · Week 5–8

    Online report · not medically verified

    3.75 mg GHK-Cu + 750 µg × KPV/BPC-157/TB-500 · 22.5 U · once per day · not reliably established

  • KLOW blend · Week 9–12 · taper

    Online report · not medically verified

    2.5 mg GHK-Cu + 500 µg × KPV/BPC-157/TB-500 · 15 U · once per day · not reliably established

  • KLOW blend · pause

    Online report · not medically verified

    — · 2–4 weeks / 4 weeks · not reliably established

A U figure only applies to the source's exact composition, concentration and device scale. Without all three, it cannot be transferred to another blend vial or pen.

mg and µg: substance amount · ml: liquid volume. Depending on the product, U can mean a device scale or units of activity. IU and USP U are activity units, not ml or pen clicks. These measures are not interchangeable.

More factsNon-standardised blend · Blends & catalogue terms
Classification
Non-standardised blend · Blends & catalogue terms
Research focus
Not a standardised medicinal name. Linked to skin, inflammation and repair themes; composition and effects are unconfirmed.
Evidence
Anecdotal
Status
Not FDA/EMA approved

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

Only for the defined 80 mg format — 50:10:10:10 mg GHK-Cu/KPV/BPC-157/TB-500 in +3 ml: 1 U calculates to roughly 167 µg GHK-Cu and 33 µg each of the other three components. Not a recommendation.

Profile evidence level: anecdotal.

Timing

The reference describes once daily with stepped U-100 amounts. No clinical combination trial exists.

No individual recommendation.

Cycle/duration

Online sources cite 4–6 weeks plus a 2–4 week break, or longer stepped plans; safety and long-term consequences are unknown.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Without individual amounts and joint stability data there is no verified recipe. Correct arithmetic does not establish compatibility.

Ratio-specific blend calculator

For the selected explicitly stated composition, this calculates total and per-component amounts for a U-100 draw. The ratio remains fixed to the chosen example.

The calculation uses final volume, which is not automatically the amount of water added. Excipients can change the volume; a concentration specified by the manufacturer takes priority.

Assumed composition

50 mg GHK-Cu + 10 mg KPV + 10 mg BPC-157 + 10 mg TB-500

Pre-blended vial

Documented calculation points

What the selected U-100 amount contains mathematically

GHK-Cu: 1.25 mg · KPV: 250 µg · BPC-157: 250 µg · TB-500: 250 µg

More calculation values

Total concentration

26.667 mg/ml

Volume

0.075 ml

Total amount in draw

2 mg

Calculated draws

40

Concentration per component

GHK-Cu: 16.667 mg/ml · KPV: 3.333 mg/ml · BPC-157: 3.333 mg/ml · TB-500: 3.333 mg/ml

Calculation aid only, not dosage, reconstitution or use advice. Use only when identity, each component amount and the ratio are independently confirmed. U-100 means 100 units per ml; other syringe scales are not interchangeable.

Complete ratio and U-100 examplesEach row applies only to the stated composition and assumed final volume. A different ratio produces different component amounts.

KLOW 80 mg · 50/10/10/10 · 3 ml

7.5 U

GHK-Cu: 1.25 mg · KPV: 250 µg · BPC-157: 250 µg · TB-500: 250 µg

Assumed final solution volume
3 ml
Volume
0.075 ml
Total amount in draw
2 mg

KLOW 80 mg · 50/10/10/10 · 3 ml

15 U

GHK-Cu: 2.5 mg · KPV: 500 µg · BPC-157: 500 µg · TB-500: 500 µg

Assumed final solution volume
3 ml
Volume
0.15 ml
Total amount in draw
4 mg

KLOW 80 mg · 50/10/10/10 · 3 ml

22.5 U

GHK-Cu: 3.75 mg · KPV: 750 µg · BPC-157: 750 µg · TB-500: 750 µg

Assumed final solution volume
3 ml
Volume
0.225 ml
Total amount in draw
6 mg

KLOW 80 mg · 50/10/10/10 · 3 ml

1 U

GHK-Cu: 166.7 µg · KPV: 33.3 µg · BPC-157: 33.3 µg · TB-500: 33.3 µg

Assumed final solution volume
3 ml
Volume
0.01 ml
Total amount in draw
266.7 µg

KLOW 80 mg · 50/10/10/10 · 2 ml

1 U

GHK-Cu: 250 µg · KPV: 50 µg · BPC-157: 50 µg · TB-500: 50 µg

Assumed final solution volume
2 ml
Volume
0.01 ml
Total amount in draw
400 µg

KLOW 80 mg · 50/10/10/10 · 2 ml

7.5 U

GHK-Cu: 1.875 mg · KPV: 375 µg · BPC-157: 375 µg · TB-500: 375 µg

Assumed final solution volume
2 ml
Volume
0.075 ml
Total amount in draw
3 mg

KLOW 80 mg · 50/10/10/10 · 2 ml

15 U

GHK-Cu: 3.75 mg · KPV: 750 µg · BPC-157: 750 µg · TB-500: 750 µg

Assumed final solution volume
2 ml
Volume
0.15 ml
Total amount in draw
6 mg

KLOW 80 mg · 50/10/10/10 · 4 ml

1 U

GHK-Cu: 125 µg · KPV: 25 µg · BPC-157: 25 µg · TB-500: 25 µg

Assumed final solution volume
4 ml
Volume
0.01 ml
Total amount in draw
200 µg

KLOW 80 mg · 50/10/10/10 · 4 ml

10 U

GHK-Cu: 1.25 mg · KPV: 250 µg · BPC-157: 250 µg · TB-500: 250 µg

Assumed final solution volume
4 ml
Volume
0.1 ml
Total amount in draw
2 mg

KLOW 80 mg · 50/10/10/10 · 4 ml

20 U

GHK-Cu: 2.5 mg · KPV: 500 µg · BPC-157: 500 µg · TB-500: 500 µg

Assumed final solution volume
4 ml
Volume
0.2 ml
Total amount in draw
4 mg
All preparation informationProduct details and calculation examples from the available sources.

'KLOW' is not standardised. No blanket table without a confirmed 50:10:10:10 mg ratio, total volume, salt forms and batch identity.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Community and vendor shorthand for a non-standardised multi-peptide blend

KLOW blend is classified as “Community and vendor shorthand for a non-standardised multi-peptide blend”. Not a standardised medicinal name. Linked to skin, inflammation and repair themes; composition and effects are unconfirmed. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Multi-peptide repair blend

This looks at how several individually researched peptides are combined by vendors into a shared blend, similar to mixing several ingredients into a new recipe that has not itself been tested. Individual components are usually studied separately, not the specific combination.

02

Copper-binding tripeptide

This studies how a short peptide binds copper ions and may support cell signalling in skin tissue, similar to a transport container for an important trace element. Collagen markers and cell activity in skin models are measured.

03

Tripeptide fragment

This examines the function of a very short building block made of only three amino acids, comparable to a very short word within a long sentence. Cell signalling or binding behaviour in the lab is typically measured.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Stack and blend discussion

Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.

Skin and hair anecdotes

Users exchange personal impressions of skin appearance, wrinkle depth, or hair growth after using cosmetically marketed peptides, usually based on their own photos rather than measurement devices. Such subjective impressions and marketing claims are not proof of a confirmed effect.

Vendor marketing claims

Vendors often advertise products with broad efficacy claims, comparison tables against competitors, and customer quotes. Such marketing statements are driven by sales interest and do not constitute independent scientific proof of efficacy.

Adverse effects and safety risks

  • Blends combine not only possible effects but also uncertainty, interactions, dosing errors and stability problems. An effect cannot be assigned reliably to one component.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • No use should be inferred without full qualitative and quantitative composition, batch testing and stability data; every comorbidity and medicine adds concern.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No validated monitoring exists for non-standardised blends. Individual lab values cannot make an unknown composition or interaction safe.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Anecdotal

Composition and effects are unconfirmed and not standardised.

Clinical evidence

Claims rely mostly on personal experience reports and vendor statements rather than controlled studies.

KLOW extends the GLOW blend with an additional tripeptide, but remains equally a non-standardised vendor term.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not FDA/EMA approved

No FDA- or EMA-approved medicinal product; efficacy and safety are not established.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile